# Evommune Inc. (EVMN)

Source: https://www.quantisnow.com/company/EVMN
Generated: 2026-10-31T09:27:47.381Z

- Ticker: EVMN
- Exchange: NYSE
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2025
- SEC CIK: 0002044725

## Latest EVMN news and filings

- 2026-10-20 11:36 UTC [Analyst Coverage Resumed] [Morgan Stanley resumed coverage on Evommune with a new price target](https://www.quantisnow.com/insight/morgan-stanley-resumed-coverage-on-evommune-with-a-new-price-6751430)
- 2026-10-15 20:28 UTC [SEC Form 4] [SEC Form 4 filed by Evommune Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-evommune-inc-6748204)
- 2026-10-12 12:49 UTC [Analyst Coverage Initiated] [UBS initiated coverage on Evommune with a new price target](https://www.quantisnow.com/insight/ubs-initiated-coverage-on-evommune-with-a-new-price-target-6743587)
- 2026-10-01 12:01 UTC [SEC Form 8-K] [Evommune Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/evommune-inc-filed-sec-form-8-k-regulation-fd-disclosure-financial-6731521)
- 2026-10-01 12:00 UTC [Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress](https://www.quantisnow.com/insight/evommune-presents-late-breaking-phase-2a-proof-of-concept-data-evaluating-evo301-in-6731462)
- 2026-09-23 20:05 UTC [SEC Form 8-K] [Evommune Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/evommune-inc-filed-sec-form-8-k-regulation-fd-disclosure-financial-6724142)
- 2026-09-23 20:05 UTC [Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress](https://www.quantisnow.com/insight/evommune-announces-late-breaker-presentation-of-phase-2a-data-for-evo301-6724127)
- 2026-09-15 12:30 UTC [SEC Form 8-K] [Evommune Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/evommune-inc-filed-sec-form-8-k-regulation-fd-disclosure-financial-6715525)
- 2026-09-08 21:43 UTC [Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis](https://www.quantisnow.com/insight/evommune-announces-top-line-results-from-evo756-phase-2b-trial-in-6708787)
- 2026-08-26 12:24 UTC [Analyst Coverage Initiated] [Needham initiated coverage on Evommune with a new price target](https://www.quantisnow.com/insight/needham-initiated-coverage-on-evommune-with-a-new-price-target-6695075)
- 2026-08-14 20:17 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Evommune Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-evommune-inc-6683015)
- 2026-08-14 14:38 UTC [SEC Form SCHEDULE 13G filed by Evommune Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-evommune-inc-6682300)
- 2026-08-06 20:10 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Evommune Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-evommune-inc-6669043)
- 2026-08-06 20:09 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Evommune Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-evommune-inc-6669016)
- 2026-08-06 20:06 UTC [SEC Form 8-K] [Evommune Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/evommune-inc-filed-sec-form-8-k-results-of-operations-and-6668864)
- 2026-08-06 20:05 UTC [Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights](https://www.quantisnow.com/insight/evommune-reports-second-quarter-2026-financial-results-and-provides-business-6668630)
- 2026-07-30 12:01 UTC [SEC Form 8-K] [Evommune Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/evommune-inc-filed-sec-form-8-k-regulation-fd-disclosure-financial-6655161)
- 2026-07-30 12:00 UTC [Conference Announcement] [Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis](https://www.quantisnow.com/insight/evommune-initiates-phase-2b-clinical-trial-of-mrgprx2-inhibitor-evo756-6655127)
- 2026-07-16 21:03 UTC [SEC Form SCHEDULE 13G filed by Evommune Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-evommune-inc-6640080)
- 2026-07-10 23:59 UTC [Insider Buy] [Chief Financial Officer Carver Kyle bought $13,260 worth of shares (1,000 units at $13.26), increasing direct ownership by 2% to 60,335 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-carver-kyle-bought-13260-worth-of-shares-6634571)
- 2026-07-09 00:00 UTC [Insider Buy] [Director Kirsch Arthur S bought $133,000 worth of shares (10,000 units at $13.30) (SEC Form 4)](https://www.quantisnow.com/insight/director-kirsch-arthur-s-bought-133000-worth-of-shares-10000-6632078)
- 2026-06-30 12:27 UTC [Analyst Downgrade] [Evommune downgraded by H.C. Wainwright](https://www.quantisnow.com/insight/evommune-downgraded-by-hc-wainwright-6620094)
- 2026-06-29 13:41 UTC [Analyst Downgrade] [Evommune downgraded by William Blair](https://www.quantisnow.com/insight/evommune-downgraded-by-william-blair-6618571)
- 2026-06-29 12:35 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Evommune Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-evommune-inc-6618414)
- 2026-06-29 12:32 UTC [SEC Form 8-K] [Evommune Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/evommune-inc-filed-sec-form-8-k-regulation-fd-disclosure-other-6618411)
- 2026-06-29 12:30 UTC [Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria](https://www.quantisnow.com/insight/evommune-announces-top-line-results-from-evo756-phase-2b-trial-in-6618392)
- 2026-06-25 00:00 UTC [SEC Form 4] [Chief of Dev. Operations Drew Janice Suzann exercised 20,000 shares at a strike of $3.15 and sold $452,600 worth of shares (20,000 units at $22.63) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/chief-of-dev-operations-drew-janice-suzann-exercised-20000-shares-6614816)
- 2026-06-25 00:00 UTC [SEC Form 4] [Chief Scientific Officer Patel Jeegar Pravinkumar exercised 1,488 shares at a strike of $3.84 and sold $33,480 worth of shares (1,488 units at $22.50) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/chief-scientific-officer-patel-jeegar-pravinkumar-exercised-1488-shares-at-6614813)
- 2026-06-24 23:59 UTC [SEC Form 4] [President & CEO Pena Luis C. sold $168,917 worth of shares (7,438 units at $22.71) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 630,458 units (SEC Form 4)](https://www.quantisnow.com/insight/president-ceo-pena-luis-c-sold-168917-worth-of-shares-6614808)
- 2026-06-04 00:04 UTC [SEC Form 4] [SEC Form 4 filed by Director Mcgraw Benjamin F Iii](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-mcgraw-benjamin-f-iii-6588215)
- 2026-06-04 00:03 UTC [SEC Form 4] [SEC Form 4 filed by Director Kirsch Arthur S](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-kirsch-arthur-s-6588212)
- 2026-06-04 00:03 UTC [SEC Form 4] [Director Cohen David E sold $123,094 worth of shares (6,056 units at $20.33) as part of a pre-agreed trading plan, decreasing direct ownership by 26% to 17,609 units (SEC Form 4)](https://www.quantisnow.com/insight/director-cohen-david-e-sold-123094-worth-of-shares-6056-6588211)
- 2026-06-04 00:02 UTC [SEC Form 4] [Chief Scientific Officer Patel Jeegar Pravinkumar sold $379,462 worth of shares (16,687 units at $22.74) as part of a pre-agreed trading plan and exercised 13,512 shares at a strike of $3.84, decreasing direct ownership by 6% to 46,403 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-scientific-officer-patel-jeegar-pravinkumar-sold-379462-worth-of-6588210)
- 2026-06-04 00:02 UTC [SEC Form 4] [President & CEO Pena Luis C. sold $381,736 worth of shares (16,787 units at $22.74) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 637,896 units (SEC Form 4)](https://www.quantisnow.com/insight/president-ceo-pena-luis-c-sold-381736-worth-of-shares-6588208)
- 2026-06-02 20:37 UTC [SEC Form 144] [SEC Form 144 filed by Evommune Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-evommune-inc-6584626)
- 2026-06-02 20:08 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Evommune Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-evommune-inc-6584180)
- 2026-06-02 20:07 UTC [SEC Form 8-K] [Evommune Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/evommune-inc-filed-sec-form-8-k-submission-of-matters-to-6584158)
- 2026-06-02 00:00 UTC [SEC Form 4] [Chief Business & Legal Officer Moss Gregory S. exercised 14,223 shares at a strike of $1.71 and sold $324,711 worth of shares (14,223 units at $22.83) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/chief-business-legal-officer-moss-gregory-s-exercised-14223-shares-6582753)
- 2026-06-01 23:59 UTC [SEC Form 4] [Chief Financial Officer Carver Kyle exercised 15,000 shares at a strike of $2.99 and sold $415,117 worth of shares (18,175 units at $22.84) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 59,335 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-carver-kyle-exercised-15000-shares-at-a-6582749)
- 2026-06-01 20:46 UTC [SEC Form 144] [SEC Form 144 filed by Evommune Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-evommune-inc-6582167)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/EVMN
- RSS and alerts for EVMN: https://www.quantisnow.com/docs/rss-feeds.md